

### Schedule of Assessments

Measures/Procedures		Year 1		Year 2		Year 3		Year 4	
		Month 0	Month 6	Month 12	Month 18	Month 24	Month 30	Month 36	Month 42
Neuromed	Basic demographics	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Vital Signs								
	Height	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Weight	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Blood pressure	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Anthropometry								
	Waist circumference	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Hip circumference	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Arm circumference	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Fried Frailty Index	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Neuromedical exam								
	Cranial nerve function	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Motor strength and tone	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Reflexes	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Sensory perception	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Coordination	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Gait	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Medication Summary	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	ART Medication	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	†Visual analog scale for ART adherence	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Medical comorbidities	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	COVID questionnaire	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Chronic pain questionnaire	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	TBI questionnaire: BISQ-7SF	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	†,*CD4 Nadir	T1, T2							
	†,*ARV history	T1, T2							
	Blood draw								
	CBC with differential	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	†T-cell enumeration	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	†HIV viral load	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Comprehensive metabolic panel	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
	Lipid panel	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
HgBA1c	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1	
PT/INR	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1	
C-reactive protein (HS)	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1	

Measures/Procedures	Year 1		Year 2		Year 3		Year 4	
	Month 0	Month 6	Month 12	Month 18	Month 24	Month 30	Month 36	Month 42
Anti-nucleocapsid SARS-CoV-2 serology	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
RPR/syphilis screen	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Hepatitis serologies	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
‡Rapid HIV	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Urinalysis/Toxicology								
Amphetamines	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Barbiturates	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Benzodiazepines	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Cannabinoids	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Cocaine	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Opiates	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Phencyclidine	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Methadone	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Oxycodone	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Tricyclic antidepressants	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Buprenorphine	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Methamphetamine	T1, T2	T1	T1, T2	T1	T1, T2	T1	T1, T2	T1
Lumbar Puncture (optional)								
CSF glucose	T1, T2		T1, T2		T1, T2		T1, T2	
CSF protein and albumin	T1, T2		T1, T2		T1, T2		T1, T2	
CSF cell count	T1, T2		T1, T2		T1, T2		T1, T2	
†CSF HIV viral load	T1, T2		T1, T2		T1, T2		T1, T2	
Neuropsych								
Behavioral Notes	T1, T2		T1, T2		T1, T2		T1, T2	
Activities of Daily Living	T1, T2		T1, T2		T1, T2		T1, T2	
Patient's Assessment of Own Functioning (PAOFI)-6	T1, T2		T1, T2		T1, T2		T1, T2	
<sup>a</sup> WRAT4 Reading	T1, T2							
Trail Making Test- Part A	T1, T2		T1, T2		T1, T2		T1, T2	
Trail Making Test- Part B	T1, T2		T1, T2		T1, T2		T1, T2	
WAIS-III Letter-Number Sequencing	T1, T2		T1, T2		T1, T2		T1, T2	
FAS Verbal Fluency	T1, T2		T1, T2		T1, T2		T1, T2	
Hopkins Verbal Learning Test - Revised	T1, T2		T1, T2		T1, T2		T1, T2	
Animal Verbal Fluency	T1, T2		T1, T2		T1, T2		T1, T2	
Grooved Pegboard Test	T1, T2		T1, T2		T1, T2		T1, T2	
Brief Visuospatial Memory Test - Revised	T1, T2		T1, T2		T1, T2		T1, T2	

Measures/Procedures	Year 1		Year 2		Year 3		Year 4	
	Month 0	Month 6	Month 12	Month 18	Month 24	Month 30	Month 36	Month 42
Boston Naming Test	T1, T2		T1, T2		T1, T2		T1, T2	
University of Pennsylvania Smell Identification Test-Brief	T1, T2		T1, T2		T1, T2		T1, T2	
NIH Toolbox Flanker Test	T1, T2		T1, T2		T1, T2		T1, T2	
Neurobehavioral Screen	T2	T1	T2	T1	T2	T1	T2	T1
Perceived Stress Scale	T2	T1	T2	T1	T2	T1	T2	T1
Snaith-Hamilton Pleasure Scale (Anhedonia)	T2	T1	T2	T1	T2	T1	T2	T1
Toronto Alexithymia Scale	T2	T1	T2	T1	T2	T1	T2	T1
FrSBe Apathy	T2	T1	T2	T1	T2	T1	T2	T1
FrSBe Disinhibition	T2	T1	T2	T1	T2	T1	T2	T1
NIH Toolbox Fear/Anxiety	T2	T1	T2	T1	T2	T1	T2	T1
NIH Toolbox General Life Satisfaction	T2	T1	T2	T1	T2	T1	T2	T1
NIH Toolbox Loneliness	T2	T1	T2	T1	T2	T1	T2	T1
NIH Toolbox Instrumental Support	T2	T1	T2	T1	T2	T1	T2	T1
<sup>b</sup> WHODAS 2.0	T2	T1						
<sup>b</sup> DSM-5-TR Cross Cutting Symptom Measure	T2	T1						
Alcohol Use Disorders and Associated Disabilities Interview Schedule-5 (AUDADIS-5)	T2	T1	T2	T1	T2	T1	T2	T1
Pittsburgh Sleep Quality Index-PSQI	T2	T1	T2	T1	T2	T1	T2	T1
Beck Depression Inventory-II	T2	T1	T2	T1	T2	T1	T2	T1
<sup>b</sup> GAD-7	T2	T1						
<sup>b</sup> PHQ-9	T2	T1						
Kreek-McHugh-Schluger-Kellogg Scale (KMSK)	T2	T1	T2	T1	T2	T1	T2	T1
Neuroimaging	MRI (optional)							
	T1w	T1, T2			T1, T2			
	T2w	T1, T2			T1, T2			
	FLAIR	T1, T2			T1, T2			
	Resting State fMRI	T1, T2			T1, T2			
	PC Arterial Spin Labeling	T1, T2			T1, T2			
	MRS frontal gray	T1, T2			T1, T2			
	MRS frontal white	T1, T2			T1, T2			

Notes:

Data collection continues beyond Year 4, with a repeating schedule of assessments

T1= Tier 1 (Medically/socially unstable, require close follow up)

T2 = Tier 2 (Average acuity for organ donation study)

†Obtained only from individuals living with HIV (PWH)

‡Obtained only from individuals without HIV infection (PWoH)

\*May be abstracted/supplemented by a review of medical or pharmacy records

<sup>a</sup>New measure that is administered only once at baseline to newly enrolled participants

<sup>b</sup>New measure that is administered only once at baseline to new participants, or at the next onsite visit to existing participants